Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioatla Inc BCAB

Healthcare Biotechnology
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL... see more

Recent & Breaking News (NDAQ:BCAB)

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

GlobeNewswire November 7, 2024

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

GlobeNewswire October 31, 2024

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire October 4, 2024

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

GlobeNewswire October 1, 2024

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

GlobeNewswire September 23, 2024

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

GlobeNewswire September 16, 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

GlobeNewswire September 9, 2024

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 28, 2024

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

GlobeNewswire August 8, 2024

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

GlobeNewswire August 1, 2024

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

GlobeNewswire July 25, 2024

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

GlobeNewswire July 23, 2024

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

GlobeNewswire June 27, 2024

BioAtla to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 23, 2024

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

GlobeNewswire May 14, 2024

BioAtla to Participate in the Citizens JMP Life Sciences Conference

GlobeNewswire May 8, 2024

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

GlobeNewswire May 7, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

GlobeNewswire May 6, 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 24, 2024